… We investigated the pharmacokinetic/pharmacodynamic (PK/PD) relationship, … Dabigatran
is a direct thrombin inhibitor that does not rely on endogenous plasma levels of anti-thrombin …

… For the direct thrombin inhibitor dabigatran etexilate, a calibrated diluted thrombin time or …
For dabigatran, this is the inhibition of thrombin formation and for anti–factor Xa drugs, the …

… Alternative oral agents that address these shortcomings may improve … dabigatran
etexilate (DE), a direct thrombin inhibitor, are established in adults; pharmacokinetic/pharmacodynamic …

… on the pharmacokinetics and pharmacodynamics of DOACs and of strategies proposed to
adjust doses according to the level of renal dysfunction. The pharmacokinetic characteristics …

… the pharmacokinetics of dabigatran (factor IIa/thrombin inhibitor) and apixaban, edoxaban
and rivaroxaban (factor Xa) inhibitors. … The oral bioavailability of dabigatran etexilate is low, at …

… Dabigatran etexilate is an oral direct thrombin inhibitor that is approved for use to reduce
the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) …

… To our knowledge, this is the first report of an oral direct thrombin inhibitor in a … Clinical
pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate…

… The DOACs, dabigatran (a reversible direct thrombin inhibitor) and the … Dabigatran can
be orally administered as the prodrug, dabigatran etexilate which differs from dabigatran by an …

… to the active direct thrombin inhibitor (factor IIa) dabigatran, after absorption. … Clinical
pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. …

… with the direct thrombin inhibitor—Dabigatran (Pradaxa, … replacement who received
dabigatran etexilate 150 mg and … , dabigatran etexilate, an oral direct thrombin inhibitor, does not …